Chemotherapy and immunity in opportunistic parasitic infections in AIDS.
Parasitic diseases are endemic in parts of the tropics, but there is no convincing evidence that their prevalence or incidence is increasing due to the HIV epidemic. Available scientific data on parasitic infections in patients with the Acquired Immunodeficiency Syndrome (AIDS) suggests a predominance of Pneumocystis carinii, Toxoplasma gondii and Cryptosporidium spp. For reasons which are unclear, parasitic infections such as Plasmodium falciparum, Strongyloides stercoralis and Entamoeba histolytica, where cell-mediated immune responses are also thought to be significant, do not appear to be opportunists of importance. It is being increasingly recognized that chemotherapy for parasitic diseases has a host-dependent component, although scientific data on this subject remain scanty. The management of opportunistic parasitic infections in patients infected with HIV is dogged by failures and relapses, aptly illustrating the notion of the relationship between chemotherapy and the immune response. This review discusses the immunity and chemotherapy of opportunistic parasite infections in patients infected with the Human Immunodeficiency Virus (HIV).
Zumla
A
A
Center for Infectious Diseases, University of Texas, School of Medicine and Public Health, Houston.
Croft
S L
SL
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000276:immunology*; D000818:Animals; D006801:Humans; D007111:Immunity, Cellular; D051379:Mice; D010272:Parasitic Diseases / Q000188:drug therapy* / Q000276:immunology*